日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study

既往接受过英夫利昔单抗或阿巴西普治疗的类风湿性关节炎患者对阿巴西普的临床反应和耐受性：ATTEST 研究的开放标签扩展研究

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/annrheumdis-2011-200316
Schiff, Michael; Keiserman, Mauro; Codding, Christine; Songcharoen, Suthin; Berman, Alberto; Nayiager, Sauithree; Saldate, Cristina; Aranda, Richard; Becker, Jean-Claude; Nys, Marleen; le Bars, Manuela; Reed, Diane Moniz; Poncet, Coralie; Dougados, Maxime
关节炎
TES
发表日期：2011
文献求助 收藏

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

ATTEST 研究：一项 III 期、多中心、随机、双盲、安慰剂对照研究，旨在评估阿巴西普或英夫利昔单抗与安慰剂相比，对甲氨蝶呤疗效不佳的类风湿性关节炎患者的疗效和安全性。

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/ard.2007.080002
Schiff, M; Keiserman, M; Codding, C; Songcharoen, S; Berman, A; Nayiager, S; Saldate, C; Li, T; Aranda, R; Becker, J-C; Lin, C; Cornet, P L N; Dougados, M
关节炎
TES
发表日期：2008
文献求助 收藏